All In Biotech

Drug Trial Radar · NCT05328908

A Study of Nivolumab-relatlimab Fixed-dose Combination Versus Regorafenib or TAS-102 in Participants With Later-lines of Metastatic Colorectal Cancer

A Phase 3, Randomized, Open-label Study of Relatlimab-nivolumab Fixed-dose Combination Versus Regorafenib or Trifluridine + Tipiracil (TAS-102) for Participants With Later-lines of Metastatic Colorectal Cancer

Last checked: Nov 19, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. Randomized with 769 participants. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

769

Actual

Start

Apr 28, 2022

Primary completion

Jul 14, 2025

Study completion Jul 14, 2025

Sponsor

Lead sponsor
Bristol-Myers SquibbBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Apr 14, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate relatlimab in combination with nivolumab, administered as a fixed-dose combination (nivolumab-relatlimab FDC, also referred to as BMS-986213) for the treatment of non-microsatellite instability high (MSI-H)/deficient mismatch repair (dMMR) metastatic colorectal cancer (mCRC) participants who failed at least 1 but no more than 4 prior lines of therapy for metastatic disease.

Conditions

  • Colorectal Neoplasms

Interventions

  • Nivolumab-relatlimab FDCDrug

    Specified dose on specified days

  • RegorafenibDrug

    Specified dose on specified days

  • TAS-102Drug

    Specified dose on specified days

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall Survival (OS)Time frame: From date of randomization to the date of death due to any cause (Up to approxaimtely 38 months)

Locations

139 sites in 22 countries. Site status is shown where the registry gives one.

  • Local Institution - 0044

    Springdale, Arkansas

  • Local Institution - 0012

    Los Angeles, California

  • Local Institution - 0117

    Norwich, Connecticut

  • Local Institution - 0025

    Miami, Florida

  • Local Institution - 0031

    Atlanta, Georgia

  • Local Institution - 0071

    Boise, Idaho

  • Local Institution - 0081

    Fort Wayne, Indiana

  • Massachusetts General Hospital,

    Boston, Massachusetts

  • Local Institution - 0042

    Ann Arbor, Michigan

  • Local Institution - 0043

    East Brunswick, New Jersey

  • Local Institution - 0009

    Durham, North Carolina

  • Local Institution - 0082

    Cincinnati, Ohio

  • Local Institution - 0095

    Columbus, Ohio

  • Local Institution - 0147

    Philadelphia, Pennsylvania

  • Local Institution - 0008

    Charleston, South Carolina

  • Local Institution - 0096

    Sioux Falls, South Dakota

  • Local Institution - 0127

    Nashville, Tennessee

  • Local Institution - 0097

    Fort Worth, Texas

  • Local Institution - 0132

    Richmond, Virginia

  • Local Institution - 0005

    Madison, Wisconsin

  • Local Institution - 0024

    Ciudad Autónoma Buenos Aires, Argentina

  • Local Institution - 0023

    Rio Grande, Argentina

  • Local Institution - 0026

    Ciudad Autónoma Buenos Aires, B, Argentina

  • Local Institution - 0022

    Ciudad Autónoma Buenos Aires, Buenos Aires, Argentina

  • Local Institution - 0098

    Wagga Wagga, New South Wales, Australia

  • Local Institution - 0114

    Westmead, New South Wales, Australia

  • Local Institution - 0001

    Greenslopes, Queensland, Australia

  • Local Institution - 0010

    Clayton, Victoria, Australia

  • Local Institution - 0021

    Melbourne, Victoria, Australia

  • Local Institution - 0027

    Murdoch, Western Australia, Australia

  • Local Institution - 0030

    Graz, Austria

  • Local Institution - 0078

    Klagenfurt, Austria

  • Local Institution - 0131

    Salzburg, Austria

  • Local Institution - 0070

    Edegem, Belgium

  • Local Institution - 0120

    Leuven, Belgium

  • Local Institution - 0062

    Woluwé-Saint-Lambert, BRU, Belgium

  • Local Institution - 0068

    Ghent, VOV, Belgium

  • Local Institution - 0003

    Edmonton, Alberta, Canada

  • Local Institution - 0014

    Ottawa, Ontario, Canada

  • Local Institution - 0007

    Toronto, Ontario, Canada

Showing 40 of 139 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.